Trials / Conditions / Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

19 registered clinical trials studyying Alpha1-Antitrypsin Deficiency — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of NCT07326592	CSL Behring	Phase 4
Enrolling By Invitation	Preparation of IPSC for Cell Gene Editing for the Treatment of AATD NCT06892236	Fondazione IRCCS Policlinico San Matteo di Pavia	N/A
Recruiting	A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Proble NCT06512454	Takeda	—
Recruiting	Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease NCT06165341	Takeda	Phase 3
Withdrawn	A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic NCT05466747	Takeda	Phase 4
Active Not Recruiting	An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Al NCT05899673	Takeda	Phase 3
Recruiting	Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarrin NCT05677971	Takeda	Phase 3
Completed	A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhi NCT04722887	Grifols Therapeutics LLC	Phase 1 / Phase 2
Withdrawn	ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study NCT04440488	Shire	Phase 4
Completed	Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype NCT04474197	Vertex Pharmaceuticals Incorporated	Phase 2
Terminated	Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency NCT02722304	Baxalta now part of Shire	Phase 3
Completed	Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participa NCT02870309	Grifols Therapeutics LLC	Phase 1 / Phase 2
Completed	Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficienc NCT02870348	Grifols Therapeutics LLC	Phase 1 / Phase 2
Completed	GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study NCT02525861	Baxalta now part of Shire	Phase 3
Unknown	Liver Disease in Patients With alpha1-antitrypsin Deficiency NCT02929940	RWTH Aachen University	—
Completed	GLASSIA Infusion Rate Study NCT01651351	Baxalta now part of Shire	Phase 4
Terminated	Aralast alpha1-proteinase Inhibitor Surveillance Study NCT00313144	Baxalta now part of Shire	Phase 4
Completed	Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Sub NCT00157092	Baxalta now part of Shire	Phase 1 / Phase 2
Completed	Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficienc NCT00161707	Baxalta now part of Shire	Phase 1 / Phase 2